
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 20 |
| Proteolysis-targeting chimeras (PROTAC) | 5 |
| Synthetic peptide | 1 |
| Recombinant polypeptide | 1 |
| Enzyme | 1 |
Target |
Mechanism ULK1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ALK degraders [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK12 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Aug 2014 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
2-APQC ( SIRT3 ) | Cardiomegaly More | Preclinical |
Compound 29i(Southwest Jiaotong University) ( TYK2 ) | Rhinitis, Allergic More | Preclinical |
Compound 6k(Southwest Jiaotong University) | Neoplasms More | Preclinical |
M468-4456 ( ULK1 ) | Lung Cancer More | Preclinical |
Polyphyllin I(MUST) ( CTNNB x EZH2 x VEGF-C x c-Myc ) | Ovarian Cancer More | Preclinical |





